Lymerix withdrawal update
Executive Summary
FDA will update vaccines advisory committee on GlaxoSmithKline's Lymerix during the afternoon of May 21. The company withdrew the lyme disease vaccine Feb. 25, citing low demand. The committee had previously reviewed reports of safety problems with the vaccine (11"The Pink Sheet" March 4, p. 23). The meeting will be held at the Hilton in Silver Spring, Md., at 8:30 a.m...
You may also be interested in...
GSK Lymerix Withdrawn: Production Stopped, Inventory To Be Discarded
GlaxoSmithKline has ceased production of Lymerix and will not be selling its remaining inventory of the Lyme disease vaccine
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.